Key result
Angptl3 accelerates podocyte apoptosis in preclinical models while siRNA knockdown markedly reduces this injury.
Absolute Event Rate: 34.8% vs 1.89%
p-value: p=<0.0001
Angptl3 accelerates PAN-induced podocyte detachment and apoptosis in vitro, suggesting it as a potential therapeutic target for podocyte injury.
Angptl3 inhibition may protect against podocyte injury; leaves open translation to human glomerular disease.
BACKGROUND: Podocyte detachment and apoptosis are two risk factors causing podocyte loss, F-actin rearrangement is involved in detachment and apoptosis. However, the nature of events that promote detachment and apoptosis of podocytes and whether detachment occurred simultaneously with apoptosis are still unclear. Previously, it was found that angiopoietin-like3 (Angptl3) induces F-actin rearrangement in podocytes. In this study we investigate whether Angptl3 influences podocyte loss (detachment and apoptosis) and the process through which Angptl3 exactly influenced the podocyte loss. METHODS: In conditionally immortalized mice podocytes, recombinant mice Angptl3 protein (rm-Angptl3) was used to mimic Angptl3 overexpression model and transfection with small interfering RNA (siRNA) to knockdown the expression of Angptl3. Both flow cytometry analysis and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay were used to detect apoptosis. Rearrangement of F-actin was assessed using confocal microscopy. Western blot assay was used to measure levels of Angptl3, integrin α3β1, integrin-linked kinase (ILK), p53, caspase 3, and phosphorylation of integrin β1. RESULTS: In a puromycin aminonucleoside (PAN)-induced podocyte injury model, rm-Angptl3 accelerated the loss of podocytes, both detachment and apoptosis occurred, and F-actin rearrangement is involved in the process. However, knockdown of Angptl3 by siRNA markedly ameliorated these injuries. Observed effects were partially correlated with the altered integrin α3β1, ILK and p53, rather than caspase 3. CONCLUSIONS: Angptl3 is a novel factor involved in the PAN-induced podocyte loss by affecting detachment and apoptosis in vitro. This study helps to deepen the understanding of the mechanisms of podocyte loss and lays the foundation for developing a new successful therapy for podocyte injury via lower expression of Angptl3.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2015) studied Podocyte injury. Recombinant mice Angptl3 protein (rm-Angptl3) and Angptl3 siRNA vs. Control podocytes (without rm-Angptl3 or with control siRNA) was evaluated on Podocyte apoptosis rate after PAN pretreatment (p=<0.0001). In a puromycin aminonucleoside-induced podocyte injury model, recombinant Angptl3 accelerated podocyte detachment and apoptosis, whereas knockdown of Angptl3 by siRNA markedly ameliorated these injuries.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: